ASPIRED-XT: ASPirin Intervention for the REDuction of Colorectal Cancer Risk -EXTension

Sponsor
Massachusetts General Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05056896
Collaborator
National Cancer Institute/NIH/DHHS (NCI) (Other), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (NIH), National Institutes of Health (NIH) (NIH)
160
Enrollment
1
Location
2
Arms
46
Anticipated Duration (Months)
3.5
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This research study is studying a drug intervention as a possible chemoprevention strategy for colorectal cancer.

The name of the study intervention involved in this study is:
  • Low Dose Aspirin
Condition or DiseaseIntervention/TreatmentPhase
Early Phase 1

Detailed Description

This is prospective, double-blind, placebo-controlled, randomized clinical trial to measure the effects of daily low-dose (81 mg/day) aspirin on tissue, urine, plasma, and stool biomarkers associated with colorectal cancer with a focus on the effect of age. It is a direct extension of an earlier study: ASPIRED trial NCT02394769

Aspirin is part of the non-steroidal anti-inflammatory drug (NSAID) family, which are drugs routinely used for their pain-killing (analgesic), fever-reducing (antipyretic), or anti-inflammatory properties. Most NSAIDs are available as over-the-counter formulations. Substantial evidence has conclusively demonstrated that aspirin reduces the risk of colorectal polyps and cancer, yet there remains uncertainty surrounding its mode of action. Aspirin may prevent colorectal cancer through multiple interrelated biological mechanisms including the reduction of chronic inflammation, a known risk factor for colorectal cancer. Aspirin has been shown to directly affect prostaglandins, a class of biologic molecules that play important roles in controlling the normal inflammatory responses within your body. The exact mechanism by which aspirin acts to prevent colorectal cancer is still unknown.This study is looking at the mechanisms of aspirin's anti-cancer effect, which may lead to the discovery of novel specific characteristics (markers) that can be used to select patients for aspirin treatment. the study will also look at the effect age may have on these mechanisms.

The research study procedures include screening for eligibility and study treatment and scheduling two clinical research visits immediately before and after intervention with the study drug.

Participants will be randomized into two groups.

  • Arm A: Daily Placebo (no aspirin) for the duration of the study.

  • Arm B: Daily low dose aspirin (81 mg/day) for the duration of the study.

Participants may be contacted periodically after the study (no more than 1- 2 times annually) for up to 10 years to follow-up on additional information including any continued aspirin use or follow-up colonoscopy results.

It is expected that about 160 people will take part in this research study.

The National Cancer Institute (NCI) of the National Institutes of Health (NIH) is supporting this research study by providing funding for the research study.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
160 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Masking Description:
Double-Blinded
Primary Purpose:
Prevention
Official Title:
ASPIRED-XT: ASPirin Intervention for the REDuction of Colorectal Cancer Risk -EXTension
Anticipated Study Start Date :
Mar 1, 2022
Anticipated Primary Completion Date :
Jun 30, 2024
Anticipated Study Completion Date :
Dec 31, 2025

Arms and Interventions

ArmIntervention/Treatment
Experimental: Low Dose Aspirin

Participants will be randomly assigned to aspirin group and receive a daily low dose aspirin (81 mg) for the duration of the study up to 12 weeks.

Drug: Aspirin
Capsule taken orally
Other Names:
  • acetylsalicylic acid (ASA)
  • Salicylic Acid Acetate
  • Experimental: Placebo

    Participants will be randomly assigned to placebo group and receive a daily placebo capsule for the duration of the study up to 12 weeks.

    Other: Placebo
    Capsule taken orally

    Outcome Measures

    Primary Outcome Measures

    1. Change of ISC marker gene expression [2 months]

      Assess the difference in the change of ISC marker using scRNA-seq data analysis

    Secondary Outcome Measures

    1. Change in Urinary PGE-M [2 months]

      Comparing change in PGE-M between treatment groups (aspirin and placebo) using a two-sample t-test.

    2. Change in urinary Plasma GDF-15 [2 months]

      Comparing change inGDF-15 between aspirin and placebo groups, using a two-sample t-test.

    3. ChIP-seq Analysis of Colonic Epithelium [2 months]

      Analysis of the ChIP-seq data (>60 million reads, 50-bp paired end) using the publicly available Cistrome Analysis Pipeline

    4. Gene Expression Analysis of Colonic Epithelium [2 months]

      RNA-seq sequence data (> 50 million reads) will be mapped to hg19 through use of TopHat2.

    5. Change in Microbiome [2 months]

      Aspirin use and dose will be associated with microbial operational taxonomic units (OTUs) using the Biobakery3 computational analysis pipeline.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Participants must have undergone screening or surveillance colonoscopy with removal of at least one adenoma within the last 9 months.

    • Age greater than or equal to 18 years and less than 55 years or greater than or equal to 65 years at the time of enrollment This study will only include adult participants because colorectal carcinogenesis in children is more likely to be related to a cancer predisposition syndrome with distinct biological mechanisms compared with sporadic colorectal cancer in adults.

    • ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A).

    • Not currently taking aspirin (any dose) within the last 6 months.

    • The effects of aspirin on the developing human fetus are unknown. For this reason, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately.

    • Ability to understand and the willingness to sign a written informed consent document.

    Exclusion Criteria:
    • Use of any non-aspirin non-steroidal anti-inflammatory drug (NSAID) at any dose at least three times a week during the two months prior to randomization.

    • Diagnosis of inflammatory bowel disease, liver or kidney disease, bleeding diathesis.

    • Any prior diagnosis of gastrointestinal cancer (including esophageal, small intestine, colon, pancreatic), or any diagnosis of other cancers (with the exception of non-melanoma skin) in which there has been any active treatment within the last three years.

    • Participants who are receiving any other investigational agents.

    • History of allergic reactions attributed to compounds of similar chemical or biologic composition to aspirin.

    • Known diagnosis of Familial Adenomatous Polyposis (FAP) or Hereditary Non-Polyposis Colorectal Cancer (HNPCC, Lynch Syndrome).

    • Any adenoma that was not completely removed during previous colonoscopy.

    • History of aspirin intolerance, bleeding diathesis, peptic ulcer or gastrointestinal bleed, endoscopic complications, or contraindication to colonoscopy.

    • Inability or unwillingness to abstain from non-protocol use of aspirin or NSAIDs or to provide blood, urine, or stool samples or colon biopsies during the study.

    • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

    • Pregnant or breastfeeding. Pregnant women are excluded from this study because aspirin is an FDA Category D agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with aspirin, breastfeeding should be discontinued if the mother is treated with aspirin.

    • Participant must be able to swallow pills.

    • Participant is taking any anticoagulant agent (e.g. warfarin) or antiplatelet agent (e.g. clopidogrel).

    Contacts and Locations

    Locations

    SiteCityStateCountryPostal Code
    1Massachusetts General Hospital Cancer CenterBostonMassachusettsUnited States02114

    Sponsors and Collaborators

    • Massachusetts General Hospital
    • National Cancer Institute/NIH/DHHS (NCI)
    • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    • National Institutes of Health (NIH)

    Investigators

    • Principal Investigator: Andrew T Chan, MD, MPH, Massachusetts General Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Andrew T. Chan, MD, MPH, Principal Investigator, Massachusetts General Hospital
    ClinicalTrials.gov Identifier:
    NCT05056896
    Other Study ID Numbers:
    • 21-376
    • R01CA243454
    • R01CA257523
    • R35CA253185-01
    • K01DK120742-01A1
    First Posted:
    Sep 27, 2021
    Last Update Posted:
    Sep 27, 2021
    Last Verified:
    Sep 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Andrew T. Chan, MD, MPH, Principal Investigator, Massachusetts General Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 27, 2021